Weight-Loss Drugs Linked to Potential Alzheimer's Protein Reduction
A comprehensive review conducted by researchers at Anglia Ruskin University has found that GLP-1 receptor agonists, commonly used as diabetes and weight-loss medications, may have the potential to reduce the buildup of amyloid-beta and tau proteins associated with Alzheimer's disease. The review analyzed 30 studies, primarily preclinical, involving cell cultures and lab animals. The drugs, including semaglutide, liraglutide, exenatide, and dulaglutide, showed varying degrees of effectiveness in reducing these proteins. Liraglutide was noted for its consistent results in lowering amyloid-beta and tau levels. However, the review also highlighted the need for more extensive human trials, as current evidence from two small clinical trials showed mixed results.